Arafat Hossain
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Arafat Hossain has a total of 1 co-authors. Here are the top co-authors by number of shared publications:
- Takdir Hossain
Department of Pharmacy Bangabandhu Sheikh Mujibur Rahman Science and Technology University Gopalganj Bangladesh
3 shared publications
Latest Publications
- 5 October 2025
- Published by Wiley in Drug Development Research
- Vol. 86 (7) , e70167
Targeting mTOR Kinase for Cancer Treatment: A Comprehensive Review With Clinical Insights
Cancer remains a significant global health challenge, with increasing incidence and mortality rates worldwide. The mechanistic target of rapamycin (mTOR) pathway, a central regulator of cell growth, proliferation, metabolism, and survival, has emerged as a promising therapeutic target in cancer. Dysregulation of mTOR signaling is implicated in various cancers, including breast, colon, lung, renal cell carcinoma, and multiple myeloma, making it an attractive target for inhibition. This review provides a comprehensive analysis of mTOR‐targeted therapies, focusing on the clinical outcomes, efficacy, safety, and adverse effects of mTOR inhibitors. We explore the mechanisms of mTOR regulation, the impact of mTOR mutations on drug sensitivity, and the development of resistance to mTOR inhibitors. The review also highlights the potential of combination therapies and next‐generation inhibitors to overcome resistance and improve therapeutic outcomes. Key mTOR inhibitors, including rapalogs (e.g., sirolimus, everolimus) and ATP‐competitive inhibitors (e.g., MLN0128, PP242), are discussed in detail, along with their clinical applications and limitations. Additionally, we summarize the findings from major clinical trials, including FDA‐approved mTOR inhibitors like everolimus and temsirolimus, and non‐FDA‐approved inhibitors such as sapanisertib and ridaforolimus. The review underscores the importance of understanding mTOR signaling and its role in cancer progression, offering insights into the future of mTOR‐targeted therapies in oncology.
- 5 October 2025
- Published by Wiley in Drug Development Research
- Vol. 86 (7) , e70167
Targeting mTOR Kinase for Cancer Treatment: A Comprehensive Review With Clinical Insights
Cancer remains a significant global health challenge, with increasing incidence and mortality rates worldwide. The mechanistic target of rapamycin (mTOR) pathway, a central regulator of cell growth, proliferation, metabolism, and survival, has emerged as a promising therapeutic target in cancer. Dysregulation of mTOR signaling is implicated in various cancers, including breast, colon, lung, renal cell carcinoma, and multiple myeloma, making it an attractive target for inhibition. This review provides a comprehensive analysis of mTOR‐targeted therapies, focusing on the clinical outcomes, efficacy, safety, and adverse effects of mTOR inhibitors. We explore the mechanisms of mTOR regulation, the impact of mTOR mutations on drug sensitivity, and the development of resistance to mTOR inhibitors. The review also highlights the potential of combination therapies and next‐generation inhibitors to overcome resistance and improve therapeutic outcomes. Key mTOR inhibitors, including rapalogs (e.g., sirolimus, everolimus) and ATP‐competitive inhibitors (e.g., MLN0128, PP242), are discussed in detail, along with their clinical applications and limitations. Additionally, we summarize the findings from major clinical trials, including FDA‐approved mTOR inhibitors like everolimus and temsirolimus, and non‐FDA‐approved inhibitors such as sapanisertib and ridaforolimus. The review underscores the importance of understanding mTOR signaling and its role in cancer progression, offering insights into the future of mTOR‐targeted therapies in oncology.
- Open Access
- 11 August 2025
- Published by BioLuster Research Center Ltd. in Journal of Phytochemical Insights
- Vol. 2 (01) , 1-10
Assessment of the Anticancer Activity of Aegle marmelos Leaf Extracts Against Ehrlich's Ascites Carcinoma (EAC) Cell Line in Swiss Albino Mice
Cancer remains a significant health threat globally, and as a result, the demand for safer and more effective alternatives keeps growing. In this current study, we have assayed the anticancer activity of Aegle marmelos extract on Ehrlich Ascites Carcinoma (EAC) cells on Swiss Albino mice. Three extracts were prepared: a methanolic (APME), chloroform (APCE), and n-hexane (APHE) extract. These extracts were administered intraperitoneally in doses of 50 mg/kg and 100 mg/kg per dose on 6 consecutive days to mice. The anticancer activity was assessed from viable tumor cell count, with percentage (%) inhibition of cell growth, and changes in body weight of the mice that had been treated with extracts. Of all the extracts, APHE exhibited the most tumor growth inhibition (62.2% at 100 mg/kg), followed by APME (59.25%) and APCE (54.86%), compared to the standard chemotherapy drug doxorubicin (81.6% inhibition at 0.8 mg/kg/day). Mice treated with the extracts experienced less weight loss than the control group, with an approximate effect of 0.50 ± 0.06 g/day. A Brine Shrimp Lethality Bioassay demonstrated a cytotoxic dose-dependent impact, with LC50 values of 18.38, 36.79, and 46.45 micrograms per milliliter for n-hexane, methanolic, and chloroform extracts, respectively. The tumor suppression and cytotoxicity effects of Aegle marmelos extracts are probably attributable to the bioactive compounds such as flavonoids, alkaloids, and essential oils that have known apoptotic and antiproliferative activities. The extracts were not as effective as doxorubicin; however, the extracts’ natural composition and ability to reduce weight loss due to cancer indicate potential to be used in combination with or as an alternative to cancer-treating medications. Further research includes that mechanistic studies and clinical trials are needed to confirm their therapeutic potential.
- 11 August 2025
- Published by BioLuster Research Center Ltd. in Journal of Phytochemical Insights
- Vol. 2 (01) , 1-10
Open AccessAssessment of the Anticancer Activity of Aegle marmelos Leaf Extracts Against Ehrlich's Ascites Carcinoma (EAC) Cell Line in Swiss Albino Mice
Cancer remains a significant health threat globally, and as a result, the demand for safer and more effective alternatives keeps growing. In this current study, we have assayed the anticancer activity of Aegle marmelos extract on Ehrlich Ascites Carcinoma (EAC) cells on Swiss Albino mice. Three extracts were prepared: a methanolic (APME), chloroform (APCE), and n-hexane (APHE) extract. These extracts were administered intraperitoneally in doses of 50 mg/kg and 100 mg/kg per dose on 6 consecutive days to mice. The anticancer activity was assessed from viable tumor cell count, with percentage (%) inhibition of cell growth, and changes in body weight of the mice that had been treated with extracts. Of all the extracts, APHE exhibited the most tumor growth inhibition (62.2% at 100 mg/kg), followed by APME (59.25%) and APCE (54.86%), compared to the standard chemotherapy drug doxorubicin (81.6% inhibition at 0.8 mg/kg/day). Mice treated with the extracts experienced less weight loss than the control group, with an approximate effect of 0.50 ± 0.06 g/day. A Brine Shrimp Lethality Bioassay demonstrated a cytotoxic dose-dependent impact, with LC50 values of 18.38, 36.79, and 46.45 micrograms per milliliter for n-hexane, methanolic, and chloroform extracts, respectively. The tumor suppression and cytotoxicity effects of Aegle marmelos extracts are probably attributable to the bioactive compounds such as flavonoids, alkaloids, and essential oils that have known apoptotic and antiproliferative activities. The extracts were not as effective as doxorubicin; however, the extracts’ natural composition and ability to reduce weight loss due to cancer indicate potential to be used in combination with or as an alternative to cancer-treating medications. Further research includes that mechanistic studies and clinical trials are needed to confirm their therapeutic potential.
- 26 February 2025
- Published by Elsevier in European Journal of Pharmacology
- Vol. 996, 177432
Targeting PI3K in cancer treatment: A comprehensive review with insights from clinical outcomes
- 26 February 2025
- Published by Elsevier in European Journal of Pharmacology
- Vol. 996, 177432
Targeting PI3K in cancer treatment: A comprehensive review with insights from clinical outcomes
- 21 November 2024
- Published by Elsevier in European Journal of Pharmacology
- Vol. 986, 177142
A comprehensive review of targeting RAF kinase in cancer
- 21 November 2024
- Published by Elsevier in European Journal of Pharmacology
- Vol. 986, 177142
A comprehensive review of targeting RAF kinase in cancer
- Top Cited Papers
- 23 October 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 143 (Pt 2) , 113365
A comprehensive review of immune checkpoint inhibitors for cancer treatment
- 23 October 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 143 (Pt 2) , 113365
Top Cited PapersA comprehensive review of immune checkpoint inhibitors for cancer treatment
- 12 June 2024
- Published by Elsevier in European Journal of Pharmacology
- Vol. 979, 176727
Targeting the RAS upstream and downstream signaling pathway for cancer treatment
- 12 June 2024
- Published by Elsevier in European Journal of Pharmacology
- Vol. 979, 176727
Targeting the RAS upstream and downstream signaling pathway for cancer treatment